APO Research
Talk to an analyst

APO RESEARCH · REPORT

Respiratory Virus Vaccines

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Respiratory Virus Vaccines Market Outlook and Growth Opportunities 2026

31 December 2025199 pages

Choose your research edition.

Industry ResearchRespiratory Virus Vaccines Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Respiratory Virus Vaccines Industry Growth and Trends Forecast to 203297 pages · $3,450 USDMarket StructureGlobal Respiratory Virus Vaccines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032182 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Respiratory Virus Vaccines Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Respiratory Virus Vaccines Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Respiratory Virus Vaccines market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Respiratory Virus Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Respiratory Virus Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Respiratory Virus Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Respiratory Virus Vaccines market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Respiratory Virus Vaccines market include Bharat Biotech, CSL Limited, GlaxoSmithKline plc, Serum Institute of India Pvt. Ltd., Sinovac Biotech Ltd., AstraZeneca, Merck & Co., Inc. and Sanofi, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Respiratory Virus Vaccines market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Respiratory Virus Vaccines and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Respiratory Virus Vaccines sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Respiratory Virus Vaccines market size, projected growth trends, production technologies, key applications, and end-use industries.

Respiratory Virus Vaccines Segment by Company

Bharat Biotech

CSL Limited

GlaxoSmithKline plc

Serum Institute of India Pvt. Ltd.

Sinovac Biotech Ltd.

AstraZeneca

Merck & Co., Inc.

Sanofi

Respiratory Virus Vaccines Segment by Type

Recombinant Vaccines

Inactivated Vaccines

Live-attenuated Vaccines

Respiratory Virus Vaccines Segment by Application

Physician's Office

Pharmacies/Stores

Hospitals

Clinics

Respiratory Virus Vaccines Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Respiratory Virus Vaccines status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Respiratory Virus Vaccines market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Respiratory Virus Vaccines significant trends, drivers, influence factors in global and regions.

6. To analyze Respiratory Virus Vaccines competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Respiratory Virus Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Respiratory Virus Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Respiratory Virus Vaccines.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Respiratory Virus Vaccines market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Respiratory Virus Vaccines industry.

Chapter 3: Detailed analysis of Respiratory Virus Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Respiratory Virus Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Respiratory Virus Vaccines in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Respiratory Virus Vaccines Industry Trends Table 2. Respiratory Virus Vaccines Industry Drivers Table 3. Respiratory Virus Vaccines Industry Opportunities and Challenges Table 4. Respiratory Virus Vaccines Industry Restraints Table 5. Global Respiratory Virus Vaccines Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Respiratory Virus Vaccines Revenue Share by Company (2021-2026) Table 7. Global Respiratory Virus Vaccines Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Respiratory Virus Vaccines Sales Volume Share by Company (2021-2026) Table 9. Global Respiratory Virus Vaccines Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Respiratory Virus Vaccines Company Ranking, (2024-2026) & (USD Million) Table 11. Global Respiratory Virus Vaccines Key Company Manufacturing Base & Headquarters Table 12. Global Respiratory Virus Vaccines Company, Product Type & Application Table 13. Global Respiratory Virus Vaccines Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Respiratory Virus Vaccines by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Recombinant Vaccines Table 18. Significant Companies of Inactivated Vaccines Table 19. Significant Companies of Live-attenuated Vaccines Table 20. Global Respiratory Virus Vaccines Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 21. Global Respiratory Virus Vaccines Sales Volume by Type (2021-2026) & (K Units) Table 22. Global Respiratory Virus Vaccines Sales Volume by Type (2027-2032) & (K Units) Table 23. Global Respiratory Virus Vaccines Sales Volume Share by Type (2021-2026) Table 24. Global Respiratory Virus Vaccines Sales Volume Share by Type (2027-2032) Table 25. Global Respiratory Virus Vaccines Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Respiratory Virus Vaccines Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Respiratory Virus Vaccines Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Respiratory Virus Vaccines Sales Value Share by Type (2021-2026) Table 29. Global Respiratory Virus Vaccines Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Physician's Office Table 31. Significant Companies of Pharmacies/Stores Table 32. Significant Companies of Hospitals Table 33. Significant Companies of Clinics Table 34. Global Respiratory Virus Vaccines Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 35. Global Respiratory Virus Vaccines Sales Volume by Application (2021-2026) & (K Units) Table 36. Global Respiratory Virus Vaccines Sales Volume by Application (2027-2032) & (K Units) Table 37. Global Respiratory Virus Vaccines Sales Volume Share by Application (2021-2026) Table 38. Global Respiratory Virus Vaccines Sales Volume Share by Application (2027-2032) Table 39. Global Respiratory Virus Vaccines Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Respiratory Virus Vaccines Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global Respiratory Virus Vaccines Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global Respiratory Virus Vaccines Sales Value Share by Application (2021-2026) Table 43. Global Respiratory Virus Vaccines Sales Value Share by Application (2027-2032) Table 44. Global Respiratory Virus Vaccines Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 45. Global Respiratory Virus Vaccines Sales by Region (2021-2026) & (K Units) Table 46. Global Respiratory Virus Vaccines Sales Market Share by Region (2021-2026) Table 47. Global Respiratory Virus Vaccines Sales by Region (2027-2032) & (K Units) Table 48. Global Respiratory Virus Vaccines Sales Market Share by Region (2027-2032) Table 49. Global Respiratory Virus Vaccines Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Respiratory Virus Vaccines Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global Respiratory Virus Vaccines Sales Value Share by Region (2021-2026) Table 52. Global Respiratory Virus Vaccines Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global Respiratory Virus Vaccines Sales Value Share by Region (2027-2032) Table 54. Global Respiratory Virus Vaccines Market Average Price (US$/Unit) by Region (2021-2026) Table 55. Global Respiratory Virus Vaccines Market Average Price (US$/Unit) by Region (2027-2032) Table 56. Global Respiratory Virus Vaccines Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. Global Respiratory Virus Vaccines Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Respiratory Virus Vaccines Sales by Country (2021-2026) & (K Units) Table 59. Global Respiratory Virus Vaccines Sales Market Share by Country (2021-2026) Table 60. Global Respiratory Virus Vaccines Sales by Country (2027-2032) & (K Units) Table 61. Global Respiratory Virus Vaccines Sales Market Share by Country (2027-2032) Table 62. Global Respiratory Virus Vaccines Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global Respiratory Virus Vaccines Sales Value Market Share by Country (2021-2026) Table 64. Global Respiratory Virus Vaccines Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global Respiratory Virus Vaccines Sales Value Market Share by Country (2027-2032) Table 66. Bharat Biotech Company Information Table 67. Bharat Biotech Business Overview Table 68. Bharat Biotech Respiratory Virus Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 69. Bharat Biotech Respiratory Virus Vaccines Product Portfolio Table 70. Bharat Biotech Recent Development Table 71. CSL Limited Company Information Table 72. CSL Limited Business Overview Table 73. CSL Limited Respiratory Virus Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. CSL Limited Respiratory Virus Vaccines Product Portfolio Table 75. CSL Limited Recent Development Table 76. GlaxoSmithKline plc Company Information Table 77. GlaxoSmithKline plc Business Overview Table 78. GlaxoSmithKline plc Respiratory Virus Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. GlaxoSmithKline plc Respiratory Virus Vaccines Product Portfolio Table 80. GlaxoSmithKline plc Recent Development Table 81. Serum Institute of India Pvt. Ltd. Company Information Table 82. Serum Institute of India Pvt. Ltd. Business Overview Table 83. Serum Institute of India Pvt. Ltd. Respiratory Virus Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Serum Institute of India Pvt. Ltd. Respiratory Virus Vaccines Product Portfolio Table 85. Serum Institute of India Pvt. Ltd. Recent Development Table 86. Sinovac Biotech Ltd. Company Information Table 87. Sinovac Biotech Ltd. Business Overview Table 88. Sinovac Biotech Ltd. Respiratory Virus Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Sinovac Biotech Ltd. Respiratory Virus Vaccines Product Portfolio Table 90. Sinovac Biotech Ltd. Recent Development Table 91. AstraZeneca Company Information Table 92. AstraZeneca Business Overview Table 93. AstraZeneca Respiratory Virus Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. AstraZeneca Respiratory Virus Vaccines Product Portfolio Table 95. AstraZeneca Recent Development Table 96. Merck & Co., Inc. Company Information Table 97. Merck & Co., Inc. Business Overview Table 98. Merck & Co., Inc. Respiratory Virus Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Merck & Co., Inc. Respiratory Virus Vaccines Product Portfolio Table 100. Merck & Co., Inc. Recent Development Table 101. Sanofi Company Information Table 102. Sanofi Business Overview Table 103. Sanofi Respiratory Virus Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Sanofi Respiratory Virus Vaccines Product Portfolio Table 105. Sanofi Recent Development Table 106. Key Raw Materials Table 107. Raw Materials Key Suppliers Table 108. Respiratory Virus Vaccines Distributors List Table 109. Respiratory Virus Vaccines Customers List Table 110. Research Programs/Design for This Report Table 111. Authors List of This Report Table 112. Secondary Sources Table 113. Primary Sources List of Figures Figure 1. Respiratory Virus Vaccines Product Image Figure 2. Global Respiratory Virus Vaccines Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Respiratory Virus Vaccines Sales Value (2021-2032) & (US$ Million) Figure 4. Global Respiratory Virus Vaccines Sales (2021-2032) & (K Units) Figure 5. Global Respiratory Virus Vaccines Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Respiratory Virus Vaccines Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Recombinant Vaccines Image Figure 10. Inactivated Vaccines Image Figure 11. Live-attenuated Vaccines Image Figure 12. Global Respiratory Virus Vaccines Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 13. Global Respiratory Virus Vaccines Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Respiratory Virus Vaccines Sales Volume Share by Type (2021-2032) Figure 15. Global Respiratory Virus Vaccines Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Respiratory Virus Vaccines Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Respiratory Virus Vaccines Sales Value Share by Type (2021-2032) Figure 18. Physician's Office Image Figure 19. Pharmacies/Stores Image Figure 20. Hospitals Image Figure 21. Clinics Image Figure 22. Global Respiratory Virus Vaccines Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Respiratory Virus Vaccines Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global Respiratory Virus Vaccines Sales Volume Share by Application (2021-2032) Figure 25. Global Respiratory Virus Vaccines Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Respiratory Virus Vaccines Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global Respiratory Virus Vaccines Sales Value Share by Application (2021-2032) Figure 28. Global Respiratory Virus Vaccines Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 29. Global Respiratory Virus Vaccines Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global Respiratory Virus Vaccines Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global Respiratory Virus Vaccines Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America Respiratory Virus Vaccines Sales Value (2021-2032) & (US$ Million) Figure 33. North America Respiratory Virus Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe Respiratory Virus Vaccines Sales Value (2021-2032) & (US$ Million) Figure 35. Europe Respiratory Virus Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific Respiratory Virus Vaccines Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Respiratory Virus Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America Respiratory Virus Vaccines Sales Value (2021-2032) & (US$ Million) Figure 39. South America Respiratory Virus Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa Respiratory Virus Vaccines Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa Respiratory Virus Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA Respiratory Virus Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA Respiratory Virus Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA Respiratory Virus Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada Respiratory Virus Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada Respiratory Virus Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada Respiratory Virus Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico Respiratory Virus Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico Respiratory Virus Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico Respiratory Virus Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany Respiratory Virus Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany Respiratory Virus Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany Respiratory Virus Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France Respiratory Virus Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France Respiratory Virus Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France Respiratory Virus Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. Respiratory Virus Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. Respiratory Virus Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. Respiratory Virus Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy Respiratory Virus Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy Respiratory Virus Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy Respiratory Virus Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain Respiratory Virus Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain Respiratory Virus Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain Respiratory Virus Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia Respiratory Virus Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia Respiratory Virus Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia Respiratory Virus Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands Respiratory Virus Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands Respiratory Virus Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands Respiratory Virus Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries Respiratory Virus Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries Respiratory Virus Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries Respiratory Virus Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China Respiratory Virus Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China Respiratory Virus Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China Respiratory Virus Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan Respiratory Virus Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan Respiratory Virus Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan Respiratory Virus Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea Respiratory Virus Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea Respiratory Virus Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea Respiratory Virus Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India Respiratory Virus Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India Respiratory Virus Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India Respiratory Virus Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia Respiratory Virus Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia Respiratory Virus Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia Respiratory Virus Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia Respiratory Virus Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia Respiratory Virus Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia Respiratory Virus Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil Respiratory Virus Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil Respiratory Virus Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil Respiratory Virus Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina Respiratory Virus Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina Respiratory Virus Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina Respiratory Virus Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile Respiratory Virus Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile Respiratory Virus Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile Respiratory Virus Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia Respiratory Virus Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia Respiratory Virus Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia Respiratory Virus Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru Respiratory Virus Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru Respiratory Virus Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru Respiratory Virus Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Respiratory Virus Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia Respiratory Virus Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Respiratory Virus Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel Respiratory Virus Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia Respiratory Virus Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia Respiratory Virus Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE Respiratory Virus Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE Respiratory Virus Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE Respiratory Virus Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey Respiratory Virus Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey Respiratory Virus Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey Respiratory Virus Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran Respiratory Virus Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran Respiratory Virus Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran Respiratory Virus Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt Respiratory Virus Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt Respiratory Virus Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt Respiratory Virus Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Respiratory Virus Vaccines Value Chain Figure 127. Manufacturing Cost Structure Figure 128. Respiratory Virus Vaccines Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • Recombinant Vaccines
  • Inactivated Vaccines
  • Live-attenuated Vaccines
Applications
  • Physician's Office
  • Pharmacies/Stores
  • Hospitals
  • Clinics
Companies covered
  • Bharat Biotech
  • CSL Limited
  • GlaxoSmithKline plc
  • Serum Institute of India Pvt. Ltd.
  • Sinovac Biotech Ltd.
  • AstraZeneca
  • Merck & Co., Inc.
  • Sanofi

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Respiratory Virus Vaccines Sales Value (2021-2032)
  4. 1.2.2 Global Respiratory Virus Vaccines Sales Volume (2021-2032)
  5. 1.2.3 Global Respiratory Virus Vaccines Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Respiratory Virus Vaccines Market Dynamics
  1. 2.1 Respiratory Virus Vaccines Industry Trends
  2. 2.2 Respiratory Virus Vaccines Industry Drivers
  3. 2.3 Respiratory Virus Vaccines Industry Opportunities and Challenges
  4. 2.4 Respiratory Virus Vaccines Industry Restraints
3 Respiratory Virus Vaccines Market by Company
  1. 3.1 Global Respiratory Virus Vaccines Company Revenue Ranking in 2025
  2. 3.2 Global Respiratory Virus Vaccines Revenue by Company (2021-2026)
  3. 3.3 Global Respiratory Virus Vaccines Sales Volume by Company (2021-2026)
  4. 3.4 Global Respiratory Virus Vaccines Average Price by Company (2021-2026)
  5. 3.5 Global Respiratory Virus Vaccines Company Ranking (2024-2026)
  6. 3.6 Global Respiratory Virus Vaccines Company Manufacturing Base and Headquarters
  7. 3.7 Global Respiratory Virus Vaccines Company Product Type and Application
  8. 3.8 Global Respiratory Virus Vaccines Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Respiratory Virus Vaccines Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Respiratory Virus Vaccines Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Respiratory Virus Vaccines Market by Type
  1. 4.1 Respiratory Virus Vaccines Type Introduction
  2. 4.1.1 Recombinant Vaccines
  3. 4.1.2 Inactivated Vaccines
  4. 4.1.3 Live-attenuated Vaccines
  5. 4.2 Global Respiratory Virus Vaccines Sales Volume by Type
  6. 4.2.1 Global Respiratory Virus Vaccines Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Respiratory Virus Vaccines Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Respiratory Virus Vaccines Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Respiratory Virus Vaccines Sales Value by Type
  10. 4.3.1 Global Respiratory Virus Vaccines Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Respiratory Virus Vaccines Sales Value by Type (2021-2032)
  12. 4.3.3 Global Respiratory Virus Vaccines Sales Value Share by Type (2021-2032)
5 Respiratory Virus Vaccines Market by Application
  1. 5.1 Respiratory Virus Vaccines Application Introduction
  2. 5.1.1 Physician's Office
  3. 5.1.2 Pharmacies/Stores
  4. 5.1.3 Hospitals
  5. 5.1.4 Clinics
  6. 5.2 Global Respiratory Virus Vaccines Sales Volume by Application
  7. 5.2.1 Global Respiratory Virus Vaccines Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Respiratory Virus Vaccines Sales Volume by Application (2021-2032)
  9. 5.2.3 Global Respiratory Virus Vaccines Sales Volume Share by Application (2021-2032)
  10. 5.3 Global Respiratory Virus Vaccines Sales Value by Application
  11. 5.3.1 Global Respiratory Virus Vaccines Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Respiratory Virus Vaccines Sales Value by Application (2021-2032)
  13. 5.3.3 Global Respiratory Virus Vaccines Sales Value Share by Application (2021-2032)
6 Respiratory Virus Vaccines Regional Sales and Value Analysis
  1. 6.1 Global Respiratory Virus Vaccines Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Respiratory Virus Vaccines Sales by Region (2021-2032)
  3. 6.2.1 Global Respiratory Virus Vaccines Sales by Region: 2021-2026
  4. 6.2.2 Global Respiratory Virus Vaccines Sales by Region (2027-2032)
  5. 6.3 Global Respiratory Virus Vaccines Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Respiratory Virus Vaccines Sales Value by Region (2021-2032)
  7. 6.4.1 Global Respiratory Virus Vaccines Sales Value by Region: 2021-2026
  8. 6.4.2 Global Respiratory Virus Vaccines Sales Value by Region (2027-2032)
  9. 6.5 Global Respiratory Virus Vaccines Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Respiratory Virus Vaccines Sales Value (2021-2032)
  12. 6.6.2 North America Respiratory Virus Vaccines Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Respiratory Virus Vaccines Sales Value (2021-2032)
  15. 6.7.2 Europe Respiratory Virus Vaccines Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Respiratory Virus Vaccines Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Respiratory Virus Vaccines Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Respiratory Virus Vaccines Sales Value (2021-2032)
  21. 6.9.2 South America Respiratory Virus Vaccines Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Respiratory Virus Vaccines Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Respiratory Virus Vaccines Sales Value Share by Country, 2025 VS 2032
7 Respiratory Virus Vaccines Country-level Sales and Value Analysis
  1. 7.1 Global Respiratory Virus Vaccines Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Respiratory Virus Vaccines Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Respiratory Virus Vaccines Sales by Country (2021-2032)
  4. 7.3.1 Global Respiratory Virus Vaccines Sales by Country (2021-2026)
  5. 7.3.2 Global Respiratory Virus Vaccines Sales by Country (2027-2032)
  6. 7.4 Global Respiratory Virus Vaccines Sales Value by Country (2021-2032)
  7. 7.4.1 Global Respiratory Virus Vaccines Sales Value by Country (2021-2026)
  8. 7.4.2 Global Respiratory Virus Vaccines Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Respiratory Virus Vaccines Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Respiratory Virus Vaccines Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Respiratory Virus Vaccines Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Respiratory Virus Vaccines Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Respiratory Virus Vaccines Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Respiratory Virus Vaccines Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Respiratory Virus Vaccines Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Respiratory Virus Vaccines Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Respiratory Virus Vaccines Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Respiratory Virus Vaccines Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Respiratory Virus Vaccines Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Respiratory Virus Vaccines Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Respiratory Virus Vaccines Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Respiratory Virus Vaccines Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Respiratory Virus Vaccines Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Respiratory Virus Vaccines Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Respiratory Virus Vaccines Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Respiratory Virus Vaccines Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Respiratory Virus Vaccines Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Respiratory Virus Vaccines Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Respiratory Virus Vaccines Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Respiratory Virus Vaccines Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Respiratory Virus Vaccines Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Respiratory Virus Vaccines Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Respiratory Virus Vaccines Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Respiratory Virus Vaccines Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Respiratory Virus Vaccines Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Respiratory Virus Vaccines Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Respiratory Virus Vaccines Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Respiratory Virus Vaccines Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Respiratory Virus Vaccines Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Respiratory Virus Vaccines Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Respiratory Virus Vaccines Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Respiratory Virus Vaccines Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Respiratory Virus Vaccines Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Respiratory Virus Vaccines Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Respiratory Virus Vaccines Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Respiratory Virus Vaccines Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Respiratory Virus Vaccines Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Respiratory Virus Vaccines Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Respiratory Virus Vaccines Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Respiratory Virus Vaccines Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Respiratory Virus Vaccines Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Respiratory Virus Vaccines Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Respiratory Virus Vaccines Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Respiratory Virus Vaccines Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Respiratory Virus Vaccines Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Respiratory Virus Vaccines Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Respiratory Virus Vaccines Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Respiratory Virus Vaccines Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Respiratory Virus Vaccines Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Respiratory Virus Vaccines Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Respiratory Virus Vaccines Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Respiratory Virus Vaccines Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Respiratory Virus Vaccines Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Respiratory Virus Vaccines Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Respiratory Virus Vaccines Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Respiratory Virus Vaccines Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Respiratory Virus Vaccines Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Respiratory Virus Vaccines Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Respiratory Virus Vaccines Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Respiratory Virus Vaccines Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Respiratory Virus Vaccines Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Respiratory Virus Vaccines Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Respiratory Virus Vaccines Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Respiratory Virus Vaccines Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Respiratory Virus Vaccines Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Respiratory Virus Vaccines Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Respiratory Virus Vaccines Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Respiratory Virus Vaccines Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Respiratory Virus Vaccines Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Respiratory Virus Vaccines Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Respiratory Virus Vaccines Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Respiratory Virus Vaccines Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Respiratory Virus Vaccines Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Respiratory Virus Vaccines Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Respiratory Virus Vaccines Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Respiratory Virus Vaccines Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Respiratory Virus Vaccines Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Respiratory Virus Vaccines Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Respiratory Virus Vaccines Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Respiratory Virus Vaccines Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Respiratory Virus Vaccines Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Respiratory Virus Vaccines Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Bharat Biotech
  2. 8.1.1 Bharat Biotech Company Information
  3. 8.1.2 Bharat Biotech Business Overview
  4. 8.1.3 Bharat Biotech Respiratory Virus Vaccines Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Bharat Biotech Respiratory Virus Vaccines Product Portfolio
  6. 8.1.5 Bharat Biotech Recent Developments
  7. 8.2 CSL Limited
  8. 8.2.1 CSL Limited Company Information
  9. 8.2.2 CSL Limited Business Overview
  10. 8.2.3 CSL Limited Respiratory Virus Vaccines Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 CSL Limited Respiratory Virus Vaccines Product Portfolio
  12. 8.2.5 CSL Limited Recent Developments
  13. 8.3 GlaxoSmithKline plc
  14. 8.3.1 GlaxoSmithKline plc Company Information
  15. 8.3.2 GlaxoSmithKline plc Business Overview
  16. 8.3.3 GlaxoSmithKline plc Respiratory Virus Vaccines Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 GlaxoSmithKline plc Respiratory Virus Vaccines Product Portfolio
  18. 8.3.5 GlaxoSmithKline plc Recent Developments
  19. 8.4 Serum Institute of India Pvt. Ltd.
  20. 8.4.1 Serum Institute of India Pvt. Ltd. Company Information
  21. 8.4.2 Serum Institute of India Pvt. Ltd. Business Overview
  22. 8.4.3 Serum Institute of India Pvt. Ltd. Respiratory Virus Vaccines Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Serum Institute of India Pvt. Ltd. Respiratory Virus Vaccines Product Portfolio
  24. 8.4.5 Serum Institute of India Pvt. Ltd. Recent Developments
  25. 8.5 Sinovac Biotech Ltd.
  26. 8.5.1 Sinovac Biotech Ltd. Company Information
  27. 8.5.2 Sinovac Biotech Ltd. Business Overview
  28. 8.5.3 Sinovac Biotech Ltd. Respiratory Virus Vaccines Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Sinovac Biotech Ltd. Respiratory Virus Vaccines Product Portfolio
  30. 8.5.5 Sinovac Biotech Ltd. Recent Developments
  31. 8.6 AstraZeneca
  32. 8.6.1 AstraZeneca Company Information
  33. 8.6.2 AstraZeneca Business Overview
  34. 8.6.3 AstraZeneca Respiratory Virus Vaccines Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 AstraZeneca Respiratory Virus Vaccines Product Portfolio
  36. 8.6.5 AstraZeneca Recent Developments
  37. 8.7 Merck & Co., Inc.
  38. 8.7.1 Merck & Co., Inc. Company Information
  39. 8.7.2 Merck & Co., Inc. Business Overview
  40. 8.7.3 Merck & Co., Inc. Respiratory Virus Vaccines Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Merck & Co., Inc. Respiratory Virus Vaccines Product Portfolio
  42. 8.7.5 Merck & Co., Inc. Recent Developments
  43. 8.8 Sanofi
  44. 8.8.1 Sanofi Company Information
  45. 8.8.2 Sanofi Business Overview
  46. 8.8.3 Sanofi Respiratory Virus Vaccines Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Sanofi Respiratory Virus Vaccines Product Portfolio
  48. 8.8.5 Sanofi Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Respiratory Virus Vaccines Value Chain Analysis
  2. 9.1.1 Respiratory Virus Vaccines Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Respiratory Virus Vaccines Sales Mode & Process
  6. 9.2 Respiratory Virus Vaccines Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Respiratory Virus Vaccines Distributors
  9. 9.2.3 Respiratory Virus Vaccines Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst